| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8442550 | European Journal of Cancer | 2015 | 9 Pages |
Abstract
BT-WT derived benefits from more intensive chemotherapy as reflected by a reduction in relapse risk. However, the benefit of the more intensive chemotherapy to improve OS was only observed in stage I BT-WTs, by adding doxorubicin.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
M.M. van den Heuvel-Eibrink, H. van Tinteren, C. Bergeron, A. Coulomb-L'Hermine, B. de Camargo, I. Leuschner, B. Sandstedt, T. Acha, J. Godzinski, F. Oldenburger, S.L. Gooskens, J. de Kraker, G.M. Vujanic, K. Pritchard-Jones, N. Graf,